LSI USA '25 Almost at Capacity: Register Today arrow-icon
September 2024, Volume 1, No. 1
Table of Contents

Letter from the Editors

After a difficult 2022 nd 2023, healthcare venture funding appeared to take a positive turn in 2024, with momentum in the first half of the year quelling fears of a more extended downturn and fostering an environment of cautious optimism.

With today’s more stringent investor requirements in mind, it’s worth taking a look at a few of the stand-out medtech investment deals completed thus far in 2024 to help identify common threads attracting investor interest.

With a wide range of potential therapeutic applications, including chronic pain, epilepsy, movement disorders, and mental health disorders, the global neuromodulation device market continues to see significant growth, attracting new entrants.

Urology and renal devices have broad applications in dialysis centers, hospitals, and home care settings and are essential in improving quality of life and patient outcomes. Several key factors, such as the aging population and increases in incidence and prevalence, contribute to a competitive and growing market.

While the transcatheter aortic valve space is beginning to show signs of maturity, the next major objective within the structural heart market is treating valvular disease of the tricuspid and mitral valves.

Data sourced from LSI’s Global Procedure Volumes Database, which provides trusted coverage of 200+ diagnostic and therapeutic procedures in 12 major categories across 37 countries.

Celebrating the recent wins of our LSI presenting company and speaker alumni community.

The medical device industry is poised for a seismic evolution over the next decade with the emerging nexus of healthcare and AI-enabled devices that will fuel the next generation of healthcare delivery. Every stakeholder needs to prepare to think, operate, and be different, or risk becoming obsolete, says industry vets Alex Gorsky and Rick Anderson.

Brain-computer interface (BCI) has emerged as a potentially transformative, VC-backed frontier in medtech that is advancing into human clinical trials and gaining momentum. Following in the footsteps of interventional cardiology, technology and clinical innovation are coinciding to create this new opportunity, says BCI expert and Synchron founding CEO Thomas Oxley, and Synchron board director and former Dexcom CEO, Andrew Rasdal.

LSI’s CEO and Founder Scott Pantel explains why Singapore’s rapid growth into one of the world’s top Medtech and Healthtech startup ecosystems positions the country as a critical driver of global medtech advancement - offering unparalleled opportunities for strategic partnerships for companies around the globe.

This month we’re showcasing well known products and technologies offered by leading medtech companies.

For relatable jokes on our ever-evolving industry and the times in which we’re living, we’ve got the memes you need to brighten your day!

Trusted By The Companies Pioneering What’s Next

Work with us
Accelerate your business
We’re here to help you make smarter decisions and form stronger
partnerships through curated events, independent market intelligence
products and services, and digital-forward media.